The Food and Drug Administration (FDA) has approved Enhertu ® (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with ... The prescribing information for Enhertu also includes ...
The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...
The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...
Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...
Now, the date helps "further characterise the clinical benefit and safety profile of Enhertu in these patients, which will help guide treatment decisions," said Lin. The risk of breast cancer ...
DESTINY-Breast06 enrolled 866 patients (n=713 for HER2-low and n=153 for HER2-ultralow) in Asia, Europe, Australia, North America and South America. For more information about the trial, visit ...
A median progression-free survival (PFS) of 13.2 months was seen in patients randomized to Enhertu compared to 8.1 months in those randomized to chemotherapy. The confirmed objective response rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback